These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novel treatment approaches to fibrosis in scleroderma. Distler J; Distler O Rheum Dis Clin North Am; 2008 Feb; 34(1):145-59; vii. PubMed ID: 18329537 [TBL] [Abstract][Full Text] [Related]
3. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Hasegawa M; Takehara K Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279 [TBL] [Abstract][Full Text] [Related]
4. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Hawker K Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S19-25. PubMed ID: 18388796 [TBL] [Abstract][Full Text] [Related]
5. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245 [TBL] [Abstract][Full Text] [Related]
10. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Ratanatharathorn V; Pavletic S; Uberti JP Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Sakkas LI; Chikanza IC; Platsoucas CD Nat Clin Pract Rheumatol; 2006 Dec; 2(12):679-85. PubMed ID: 17133253 [TBL] [Abstract][Full Text] [Related]
12. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Chizzolini C Curr Opin Rheumatol; 2008 Nov; 20(6):707-12. PubMed ID: 18946333 [TBL] [Abstract][Full Text] [Related]
13. New treatments for SLE: cell-depleting and anti-cytokine therapies. Anolik JH; Aringer M Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407 [TBL] [Abstract][Full Text] [Related]
14. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. Sousa E; Isenberg D Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):563-74. PubMed ID: 19591785 [TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
16. New approaches of B-cell-directed therapy: beyond rituximab. Dörner T; Burmester GR Curr Opin Rheumatol; 2008 May; 20(3):263-8. PubMed ID: 18388516 [TBL] [Abstract][Full Text] [Related]
17. Emerging biological therapies in primary Sjogren's syndrome. Ramos-Casals M; Brito-Zerón P Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555 [TBL] [Abstract][Full Text] [Related]
18. Scleroderma therapy: clinical overview of current trends and future perspective. Topal AA; Dhurat RS Rheumatol Int; 2013 Jan; 33(1):1-18. PubMed ID: 23011088 [TBL] [Abstract][Full Text] [Related]
19. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. Levesque MC; St Clair EW J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms and consequences of fibrosis in systemic sclerosis. Denton CP; Black CM; Abraham DJ Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]